The Wood Laboratories, Inc., today declared results of the new analysis, demonstrating that Lexapro (escitalopram oxalate) provided greater reduction in estimation MADRS, using method LOCF and was better tolerated than Cymbalta (duloxetine), founded in percent patient, stopping processing because of disadvantage event, on processing patient with moderate in serious main depressive disorder.

Dr. Arif Kahn, Medical Director of the Northwest Clinical Research Centre and investigator in this analysis said, “These information add to ensemble of the studies, which demonstrate the clinical value Lexapro on processing of depression.”

The Patients of the estimation with DSM-IV diagnosed MDD as defined Depression Montgomery-Asberg, valuing Scale (MADRS) 26 or more was mixed for eight weeks double-blind of the processing with Lexapro 10-20 mg./dnem (the dose was fixed in 10 mg./dne during the first four weeks with additional po-titration in 20 mg./deni thereafter) or Cymbalta 60 mg./deni. Dosing two of the facility were corresponding to information in approved package is included both medicine. Primary, expected- determined, endpoint to efficiency was change with baseline for week eight in the general estimation MADRS, use the last observation transported the method (LOCF). At the beginning initially analysis, 137 patients were enrolled in lever (the hand) Lexapro analysis and 133 in lever (the hand) Cymbalta.

At the end eight week analysises, the patients Lexapro demonstrated the greater improvement than patient Cymbalta in the general estimation MADRS (LSMD, the most adapting average difference. The Proportion patient, ing on processing Lexapro, as defined 50 percents of the improvement in the general estimation MADRS, also was big when in contrast with patient in group Cymbalta (68 percents against 52 percents, p=0.011; LOCF). The Factors of the Farewell were 44 percents in group Lexapro and 38 percents in group Cymbalta, as defined general estimation MADRS 10 or less, this difference was not significant. The Factor of the improvement on MADRS was similar between group when observed analysis of the events was organized. Besides, was not no differences visible between group in ensemble of the measures of the relief somatic and bound to pains.

More patient in Lexapro group terminated eight weeks of the processing than patients in group Cymbalta, and smaller patients, getting Lexapro stopped processing because of disadvantage event in contrast with patient, getting Cymbalta.

Lexapro - selective serotonin reuptake inhibitor (SSRI), which is given for more, than 14 million adult patient in United Staff.

Lexapro Was Approved USA. Food and Administration Medicine in August 2002 both for initial and working processing main depressive disorder (MDD) in adult, and in December 2003 for processing the Universal Disorder Enxiety (PROSHLYAYTESI) in adult.

Most general disadvantage events reported Lexapro (reported at factor aproximately 5 percents or more and 2 once or more incidence visible in group were a sickness, insomnia, disorder of the ejaculation, sleepiness, raised perspiration, weariness, reduced libido, and anorgasmia. Lexapro contraindicated On patient, monoamine oxidase inhibitors (MAOIs), pimozide, or on patient with hypersensitivity on escitalopram oxalate or any one of component in Lexapro.

Either as other SSRIs, warning is specified in coadministration facilities (TCAs) by means of Lexapro. Either as the other medicine, which the hindrances with serotonin reuptake, patients must be cautioned for risk to haemorrhage bounded use the concomitant Lexapro with NSAIDs, aspirin, or the other medicine on which affect the rolling up.

The Patients with the main depressive disorder, as adult so and pediatric, can feel the deterioration to their depression and/or origin suicidal ideation and behaviours (suicidality), take they facility medication, and this risk can while significant pardon will not occur.

Though no causal role for such behaviours is not installed, patients, addressed facility must exist for clinical deterioration closely and suicidality, particularly at the beginning initially course medicine therapy, or at the time of change the dose, or increase or reduction. The Family and caregivers were be need for locked observation and relationship with prescriber. Lexapro is Not approved for use on pediatric patient.

The Timber licenses of the Laboratory Lexapro from H. Lundbeck A/S, Danish pharmaceutical company that designed escitalopram and citalopram.

Lexapro - new and the most quick-rising selective serotonin reuptake inhibitor (SSRI) and is given for more, than four million patient in USA.

Lexapro Was Approved USA. Food and Administration Medicine in August 2002 both for initial and working processing main depressive disorder. Lexapro Available as tablets and spoken decision.

The Wood Laboratories, Inc. And H. Lundbeck A/S declared preliminary first-class results from study of the phase III LEXAPRO (escitalopram oxalate) on processing teenager, old 12-17, with the Main Disorder Depressive (MDD). These results indicate that patients addressed LEXAPRO practised statistical significant improvement in of depression, as it is measured by primary endpoint of the analysis, Depression Detey, valuing Scale-Revised (CDRS-R), in contrast with CDRS-R - usually used clinician- nominal instrument, which covers 17 areas of the sign to depression important teenager, including spoiled home task, difficulty, conducting well time, public withdrawal, physical complaints, and low self-respect. It Is Expected that Additional given thereof analysis will are presented in 2008.

“Depression is a significant problem amongst teenager and often goes under-recognized and under-applied to current this age group. This support data that LEXAPRO has a potential as efficient option of the processing for teenager with depression,” said Ivan Gergel, M.D., Senior Vice President of the Scientific Deals and President of the Timber Research Institute.

I - currently on Lexapro for its depression. I have used to take Lunesta at night with lexapro previously, than go to bed and fell asleep immediately and woke;waked without drowsiness. I ceased to take Lunesta for month. My doctor raised my dose Lexapro from 10 mg. in 15 mg. I have started to take lunesta once again to help me to sleep. I бужу for the whole night for 2 days, which I returned on them. I was always tired for day and was most this jv or lying down in beds not to have an energy to do anything not even speak.